Eldecalcitol
ApprovedSmall molecule
Eldecalcitol is one of 55 small molecule programs targeting Osteoporosis. It is currently in Approved.
2
Indications
5
Total Trials
3
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
172 competitors in Osteoporosis
#DrugCompanyPhaseTrials
1Boniva
CConrado Roberto Hoffmann Filho
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
One-Alpha
RochePhase 3
Livial
PfizerPhase 3
Depo-Provera
Eli LillyPhase 3
Tymlos
RRadius Health, Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Salmon Calcitonin
NovartisPhase 3
Eldecalcitol
SShanghai Jiao Tong University Affiliated Sixth People's Hospital
Approved
Effcamgcit
UUniversity of Texas Southwestern Medical Center
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis3 trials
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Recruiting·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 4·NCT05902078·300 enrolled
Sarcopenia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Eldecalcitol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details